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ABSTRACT  
Radiotherapy is one of the most commonly used cancer treatments, with an estimate of 40% 
success that could be improved further if more efficient targeting and retention of radiation at the 
tumor site were achieved. This review focuses on the use of dendrimers in radionanotherapy, an 
emerging technology aimed to improve the efficiency of radiotherapy by implementing 
nanovectorization, an already established praxis in drug delivery and diagnosis. The labeling of 
dendrimers with radionuclides also aims to reduce the dose of radiolabeled materials, and hence 
their toxicity and tumor resistance. Examples of radiolabeled dendrimers with alpha, beta and 
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Auger electron emitters are commented, along with the use of dendrimers in boron neutron capture 
therapy (BNCT). The conjugation of radiolabeled dendrimers to monoclonal antibodies for a more 
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Since the discovery of X rays and radioactivity at the end of the 19th century, and their 
introduction into clinical practice, radiotherapy has been used, along with surgery and 
chemotherapy, as a key modality in cancer treatment. Its powerful ability to cause tumor cell death 
lays mainly in the induction of irreparable DNA damage and cell cycle arrest.1 Approximately 
50% of all cancer patients receive radiotherapy during the course of their illness2 with an estimated 
40% success.3 There are two ways to deliver radiation to the tumor sites. The most common 
approach in the clinical practice is external beam radiation, which delivers high-energy radiation 
(photons, protons or particle radiation) from outside the body to the tumor location. The second 
type is internal radiation, which is delivered by radionuclides into the tumor site. Radionuclide 
internal therapy can therefore reduce irradiation of healthy tissues with relatively low toxicity, in 
comparison to conventional chemotherapy and external beam radiotherapy.  
The therapeutic effect of internal radiotherapy is due to the delivery of alpha (α), beta (β-) or 
Auger electron emitters (Table 1) to the tumor site, resulting in tumor shrinkage or its total 
elimination, depending on the Linear Energy Transfer (LET) of the emitter (Table 2). As alpha 
particles are positively charged mono-energetic helium nuclei with the highest energy among 
particle emissions (LET ~80 keV/m), they will interact in a range of penetration in tissue from 
40 to 100 micrometers. This is consistent with the dimension of micro-metastatic lesions, so they 
are especially suited for localized irradiation of target cells with minimal toxicity to the 
surrounding normal cells. This radiation is particularly effective in killing cells,4 independently of 
their oxygenation state or cell cycle phase.5 Although human cancer cells can be eradicated in vitro 
after being hit by only a few alpha particles,6 these must reach the tumor cell nuclei to show an 
efficient cytocidal effect, not just the cell cytoplasm.7  
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Physico-chemical characteristics of Auger electrons are close with alpha particles with a tissue 
penetration from nanometers to a few micrometers. In comparison, β- particles (high energy 
electrons from β- decay) have the longest penetration range in tissue (1-12 mm). This is an 
important factor to consider regarding the size of the tumors potentially treated, as well as the 
targeting ligands and carriers for the β- radionuclide.8 The β- particle irradiation also leads to the 
generation of harmful free radical species in the presence of oxygen in tumor cells. Due to their 
lower LET compared to alpha particles, β- particles have a lower killing efficacy, so higher 
concentrations of emitters are required for a comparable effect.9 Conversely, since the long path 
of β- particles crosses multiple cells, a cross-fire effect is achieved that not only avoids the need to 
target every cancer cell with a radionuclide emitter, but also reduces the hurdle of an heterogeneous 
uptake in large tumors. 
Finally, Auger electrons are low energy atomic orbital electrons emitted after electron capture 
(EC).10 Studies in vitro have shown Auger electrons as highly effective and specific in tumor cell 
killing when used in tandem with targeting vehicles that can direct them in close proximity to 
cellular DNA.11,12  
 











80mBr 4.42 h Auger 3092.6 <10 nm 
125I 60 h Auger 185.77 10 nm 





213Bi 45.7 min α 5869 50–80 μm 
211At 7.2 h α 5870 60–80 μm 




223Ra 11.43 d α 5850 <100 μm 
169Er 9.5 d β (β): 351 1 mm 
177Lu 6.7 d β, γ (β): 500 1.6 mm 
67Cu 2.58 d β, γ (β): 577 2.2 mm 
131I 8.04 d β, γ (β): 807 2.4 mm 
89Sr 50.53 d β 1463 < 3 mm 
153Sm 1.95 d β, γ (β): 233 3 mm 
198Au 2.69 d β, γ (β): 1372.8 4.4 mm 
186Re 3.77 d β, γ (β): 1069 5 mm 
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165Dy 2.33 d β, γ (β): 1286.1 6.4 mm 
32P 14.3 d β 1710 8.7 mm 
166Ho 26.9 h β, γ (β): 1853 10.2 mm 
188Re 17 h β, γ (β): 2120 11 mm 
90Y 64.1 h β 2280 12 mm 
 
Table 2. Linear Energy Transfer (LET) of therapeutic radionuclides18   
Particle 
Decay 















* EC/IC: Electron Capture/Internal Conversion  
 
With the actual improvement in the clinical outcome of cancer treatment, the reduction of the 
toxicity related to radiation has become a priority, together with the overcoming of some primary 
limitations of radiotherapy, i.e.; injury in surrounding tissues and tumor resistance.19,20 In this 
context, nuclear medicine has recently turned the attention to new oncologic strategies based on 
the nanovectorization of radiotherapy, generating the concept of radionanomedicine.21 The core of 
radionanomedicine relies on the labelling of nanomaterials with radionuclides to reduce the 
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amounts of radiolabeled materials in vivo.22 Indeed, nanomedicine has traditionally been a major 
focus of nanotechnology.6 According to the US National Science Foundation, by 2020, nearly half 
of future pharmaceuticals will have some nanotechnology components.23,24 In recent years, there 
has been an unprecedented expansion in the field of nanomedicine with the development of new 
nanometric systems for better therapeutic efficacy and imaging quality of cancer.25 Nanosystems, 
compared to conventional medicines, have many benefits, given their nanometric size and large 
surface area-to-volume ratio, improved bioavailability, reduced toxicity, greater dose response, 
and enhanced solubility.26  
Nanosystems with long circulation times can get internalized into tumors through the leaky 
tumor vasculature and be retained in the tumor due to abnormal lymphatic drainage. This process 
is known as the enhanced permeability and retention (EPR) effect.27 However, for an efficient EPR 
effect, the physicochemical properties of the nanosystems are as important as the tumor biology. 
While, EPR effect is quite helpful to passively target nanosystems in animal models, a full 
understanding of the differences in tumor biology and clearance mechanisms between individual 
human patients has yet to be established.28  
Accordingly, innovative radionanopharmaceuticals are much awaited for targeting cancer, with 
therapeutic doses of internal radiation. Their efficacy is determined by the two constituting 
elements, the carrier and the trace amount of a radionuclide with a defined radiation type, but also 
by the injection modalities (intravenous or loco-regional injection). Ideal radiopharmaceuticals 
should transport the radioactive nuclide quantitatively to the tumor tissue, while protecting healthy 
tissues from radiation. Various kinds of carriers have been described for this purpose, including 
liposomes, carbon nanotubes, polymeric nanoparticles, nanocapsules, etc. Among them, 
dendrimers are especially appealing. Their controlled synthesis allows the preparation of well-
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defined monodisperse and globular nanovectors, characterized by a tunable size and precise 
number of peripheral groups, which determine their physicochemical properties and function 
(Fig.1). The number of peripheral groups in dendrimers increases exponentially with the 
generation number. Several approaches have been developed to conjugate dendrimers to 
paramagnetic or radionuclide chelators for MRI, fluorescence, CT, and radionuclide-based 
imaging. In addition, multimodal imaging agents with improved diagnosis accuracy have been 
described exploiting the unique structural characteristics of dendrimers. As an exhaustive analysis 
of all this literature falls outside the scope of this review, interested readers on the use of 
dendrimers in cancer imaging and chemotherapy are referred to specialized reviews.29-37 Herein, 
we will focus on the use of dendrimers in radiotherapy, including state of the art examples up to 
December 2015 and perspectives in an emerging field, which to the best of our knowledge has not 
been revised yet. 
 






1.1. NANOVECTORIZED RADIOTHERAPY DRUGS APPROVED OR UNDER CLINICAL 
TRIALS  
During the last decade, alpha (α), beta minus (β-) and Auger electron-emitting radionuclides 
have been investigated for targeted and nanovectorized radiotherapy. Fortunately, these efforts 
have resulted in four targeted β- emitters approved by FDA: 153Sm-EDTMP (Quadramet®) and 
89Sr-chloride (Metastron®) for palliation of bone metastases; and 90Y-ibritumomab (Zevalin®) and 
131I-tositumomab (Bexxar®), for the treatment of B-cell non-Hodgkin’s lymphoma. While 
Quadramet® and Metastron® consist of radioactive samarium (153Sm) complexed to a 
tetraphosphonate chelator and a strontium-89 chloride (89SrCl2) injection, respectively, Zevalin® 
and Bexxar® are radiolabeled murine antibodies, directed against the CD20 antigen expressed on 
the surface of normal and malignant B-lymphocytes.38 The latter two are good examples of the 
potential benefit of antibody-guided systemic radionuclide-targeted therapy.39-46 In addition, 
several other radiopharmaceuticals for radio-immunotherapy of tumors have been introduced into 
clinical trials. More detailed information on these clinical trials is presented in the review of 
Gudkov and coworkers (Table 3).47  
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a DOTA refers to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. 
2. DENDRIMERS AS INNOVATIVE RADIOPHARMACEUTICALS 
The history of dendrimers goes back to the late 1970s and early 1980s, when the groups of 
Vögtle,48 Newkome49 and Tomalia50 independently published the first contributions in the area. 
Since then, more than a hundred dendritic structures have been described in the search of improved 
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properties and innovative applications in fields like bio- and nanotechnology, catalysis or materials 
science.51-59 Nowadays, some of the most recognized dendritic families include polyamidoamine 
(PAMAM),60 polypropylene imine (PPI),61 and others based on polyamide,49 polyether,62 
polyester,63,64 and phosphorous-based scaffolds65 (Fig. 2).  
Dendrimers are unique among nanomaterials since their stepwise synthesis allows creating well-
defined and monodisperse structures with tunable size and number of terminal units. They have 
three main structural components: (i) an internal core, from which the dendritic branches grow, 
(ii) the layers of branches that define the dendrimer generation and, (iii) a multivalent peripheral 
shell. The number of terminal groups in dendrimers increases exponentially with the generation 
number. This characteristic is crucial to modulate the dendrimer solubility, making possible to 
overcome some fundamental issues in radiotherapy, such as solubility and dose delivery. The 
controlled architecture of dendrimers allows multiple possibilities for the simultaneous attachment 
of radionuclide chelators and targeting moieties.66  
Historically, dendrimers have been synthesized following multiple reaction steps that involve 
long reaction times, tedious purifications, and sometimes reversible reactions potentially leading 
to structural defects. This could have led to an outdated perception that dendrimer synthesis is 
complex, slow, and costly.67 Several improvements, however, have been done recently that 
simplify and fasten up the synthesis of dendrimers, including the use of: (i) orthogonal chemistries 
to avoid the need of protecting groups and so reduce the number of reaction steps;68 (ii) “click” 
chemistry for irreversible, fast, and high yield reactions;69 (iii) hypercores and hypermonomers for 
the accelerated increase of size while preserving dendrimer properties; or (iv) various types of 
heterofunctional dendrimers.70 The design principle of dendrimers has been thoroughly reviewed 
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Figure 2. Structures of common dendrimers: (a) PAMAM; (b) PPI; (c) polybenzyl ether; (d) 
polyaliphatic ester; (e) polyesteramide; (f) polycarbosilane.51 
 
2.1. RADIOLABELED DENDRIMERS IN RADIOTHERAPY 
The first successful evidence of the therapeutic use of radioactive dendrimers came from a study 
with radioactive gold-dendrimer based nanoparticles of various sizes (Fig. 3).72 In this report, 
PAMAM dendrimers were used for the targeted delivery of the radiopharmaceutical to tumors in 
vivo. Poly-198Au0 nanoparticles were synthesized from non-radioactive 197Au0-PAMAM 







Figure 3. Polymerized composite nanoparticle formed by radiation of a dendrimer network with 
simultaneous neutron activation of 197Au in the composite nanoparticles into 198Au. (Dark dots 
represent gold atoms, the organic network is grey. Reprinted from ref 72 with permission from 
Elsevier, copyright 2008. 
The increase in size of the resulting nanoparticles was due to partial crosslinking of the PAMAM 
dendrimers by the combined effect of gamma radiation and heat, while absorption of neutrons 
activated the gold component to 198Au. Biodistribution studies of both the template PAMAM 
dendrimers and the gold composites showed that positively charged nanoparticles were more 
retained in tissues than neutral or negatively charged ones. A single injection of 198Au-PAMAM 
complexes (29 nm in size) directly into a melanoma tumor mouse model resulted in more than a 
45% decrease in tumor growth within 8 days. 
 
2.1.1. DENDRIMER-β- EMMITER CONJUGATES 
The preclinical and clinical research in the field of dendrimer-β- emitters has focused on at least 
twelve radionuclides: yttrium-90 (90Y), iodine-131 (131I), lutetium-177 (177Lu), samarium-153 
(153Sm), strontium-89 (89Sr), holmium-166 (166Ho), rhenium-186 (186Re), rhenium-188 (188Re), 
copper-67 (67Cu), promethium-149 (149Pm), gold-199 (199Au) and rhodium-105 (105Rh).73 In 
addition, many radiotherapeutic β- emitters also emit a low ratio of gamma photons (γ) with energy 
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in the ideal range for nuclear imaging (80 to 200 keV). Therefore, these radionuclides have 
theranostic properties, which are valuable in clinical radiotherapeutic applications with nanometric 
systems. 
A radionuclide with excellent theranostic properties is 188Re with a ratio of 85% for - emission 
(EM = 2,12 MeV) and 15% for  emission (E = 155 keV). Yu-Mei Shen and coworkers74 used 188Re 
to radiolabel G5 PAMAM dendrimers conjugated with 2-(4-isothiocyanatobenzyl)-6-
methyldiethylene-triaminepentaacetic acid (1B4M-DTPA) as a bifunctional ligand and folic acid 
(FA) for active targeting. The labelling yield of the conjugate G5-FA-DTPA-188Re (percentage of 
incorporated radionuclide) was 67% and its radiochemical purity (the fraction of incorporated 
radioactivity that is present in the desired radiochemical form) exceeded 95%. Even though the 
conjugate showed high in vitro stability when incubated for 6 h at 37 °C in phosphate buffer saline 
(PBS, pH 7.4) or in new-born calf serum, a weak in vivo stability in mice revealed that further 
structural improvements were needed in the system.  
In a preclinical study published in 2014,75 G1 and G4 PAMAM dendrimers conjugated with 10-
[(4-carboxy-1-oxidopyridin-2-yl)methyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid 
(DO3A-pyNO-C, a DOTA-like bifunctional chelator with one methylene pyridine-N-oxide pendant 
arm) were radiolabeled with 177Lu with high radiochemical purity. Both radiolabeled dendrimers 
were stable for at least 24 h. As already seen in previous studies,76 the distribution profile of the 
G1 conjugate in organs and tissues of rats was more favorable than for G4. Conversely, the G4 
conjugate with a considerably higher number of chelating ligands per molecule enables the binding 
of a larger number of radiometals. These results showed that dendrimer-radiometal chelates might 
constitute a prospective way to radiolabel targeting agents, such as antibodies or their fragments, 
with markedly high specific activity and minimal loss of their immunoreactivity. 
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In a more recent study,77 theranostic dendrimers for targeted single-photon emission computed 
tomography (SPECT) imaging and radiotherapy of a MMP2-overexpressing xenografted glioma 
model in vivo (Fig. 4), were successfully constructed by the conjugation of a G5 PAMAM 
dendrimer with polyethylene glycol (PEG) and the targeting agents chlorotoxin (CTX) and 3-(4’-
hydroxyphenyl)propionic acid-OSu (HPAO). The dendrimer conjugates showed excellent 
cytocompatibility and could be effectively labeled with radioactive 131I with good stability and 
high radiochemical purity. For in vivo imaging experiments, 6-week-old BALB/c female nude 
mice were inoculated subcutaneously with 2 × 106 C6 cells/mouse in the right side of flank. At 
approximately 3 weeks post-injection, the tumors reached a volume of 0.5−1.0 cm3. The specific 
targeting role mediated by the attached CTX moiety onto the dendrimers was confirmed by the 
relatively higher tumor uptake of 131I-G5 NHAc-HPAO-(PEG-CTX)-(mPEG) dendrimers in 
comparison with non-targeted 131I-G5 NHAc-HPAO-(PEG-MAL)-(mPEG) dendrimers. It was 
seen that after treatment with 131I-G5 NHAc-HPAO-(PEG-CTX)-(mPEG), tumor grew more 
slowly than in mice treated with saline, Na131I, or non-targeted 131I-G5 NHAc-HPAO-(PEG-
MAL)-(mPEG). The biodistribution study of the multifunctional dendrimers, investigated by 
SPECT imaging, showed that the majority of the 131I-G5 NHAc-HPAO-(PEG-CTX)-(mPEG) or 
131I-G5 NHAc-HPAO-(PEGMAL)-(mPEG) dendrimers accumulated in the liver at 15 h post-
injection, while the heart, lung, tumor, kidney, spleen, intestines, stomach, and soft tissue had a 
relatively low accumulation of the nanosystems. In spite of the high non-specific binding to normal 
tissue, CTX enhanced the accumulation of dendrimers in tumor compared to non-targeted 
dendrimers. At 24 h post-injection, the tumor SPECT signal descended for both targeted and non-
targeted groups, indicating the dendrimer could be metabolized. Nevertheless, the SPECT signal 
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intensity of tumors treated with the CTX-targeted dendrimer was still much higher than when 
treated with the non-targeted dendrimer. 
 
Figure 4. Chlorotoxin-conjugated multifunctional dendrimers labeled with radionuclide 131I for 
imaging and radiotherapy. Reprinted with permission from ref. 77. Copyright 2015 American 
Chemical Society. 
Similar multifunctional dendrimers have been synthesized by modifying G5 PAMAM dendrimers 
with HPAO and FA linked to PEG.78 After radiolabeling with 131I (131I-G5ꞏNHAc-HPAO-PEG-
FA) the system was assayed for targeted SPECT imaging and radiotherapy, using a FA receptor-
overexpressing xenografted tumor model in vivo. The radiolabeling of the dendrimer with 131I was 
done via the chloramine T method with a radiochemical purity exceeding 97%. 131I-G5ꞏNHAc-
HPAO-PEG-FA dendrimer displayed acceptable stability in vitro for at least 27 h when stored at 
room temperature in PBS. The relative SPECT signal intensity of different organs at 6 h and 24 h 
post-injection of 131I-G5ꞏNHAc-HPAO-PEG-FA and 131I-G5ꞏNHAc-HPAO-mPEG dendrimers 
revealed that liver was the organ with the highest uptake, and a relatively low uptake from the 
other organs. Again, the tumor growth rate of mice injected with 131I-G5ꞏNHAc-HPAO-PEG-FA 
dendrimers was significantly slower than that of mice treated with saline, Na131I, and control 131I-
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G5ꞏNHAc-HPAO-mPEG dendrimers without FA. This result underlines the importance of the 
effective FA targeting, also proven by the SPECT image at the tumor site. 
Despite numerous investigations with dendrimers as conjugates for cancer drug therapy and 
imaging,29,32,79-85 there have been limited efforts in the development of radiotherapeutic 
dendrimers for image-guided radionuclide therapies. Current results are encouraging and point to 
a fruitful progress of dendrimer-chelate conjugates with bound β- emitters and target-specific 
ligands in the area. Another new axis of research could be based on loco-regional injection of 
dendrimers, especially for glioma or hepatocarcinoma treatment, as confinement of the 
radiopharmaceuticals is expected, avoiding radiotoxicity to healthy tissues. 
 
2.1.2 DENDRIMER-α EMITTER CONJUGATES 
Medically relevant α-emitting radionuclides currently available for potential therapeutic 
application are Astatine-211 (211At), Bismuth-212 (212Bi), Bismuth-213 (213Bi), Actinium-225 
(225Ac), Radium-223 (223Ra), Lead-212 (212Pb), Thorium-227 (227Th), and Terbium-149 (149Tb).86 
Recently, a pharmaceutical grade 223Ra chloride solution was the first α-emitting 
radiopharmaceutical to be approved for clinical use in the treatment of metastatic bone disease.87 
Most approaches to target α particle emitters in the past relied on conjugation with antibodies 
through chelators. The efforts to integrate dendrimers in radiotherapy with α particles are limited 
to an early report from Wu, Gansow and coworkers,88 who described a route to modify moAbs 
with a high number of chelating agents by conventional direct ligand attachment for use in 
radioimmunotherapy. This group successfully coupled with minimal loss of immunoreactivity a 
moAb with a single G2 PAMAM dendrimer carrying 10.2 of the available 12 surface primary 
amines decorated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or 
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diethylenetriaminepentaacetic acid (DTPA) bifunctional ligands. Labeling the moAb-DTPA 
complex with 212Bi resulted in at least four times greater specific activity than the previously 
obtained with a single DTPA conjugated to the moAb. In addition, radioyttrium labeling did not 
alter the immunoreactivity of the moAb-PAMAM-DOTA complex. Cold Gd(III) complexes also 
readily formed with the DOTA and DTPA-dendrimer-moAb conjugates. These positive results 
pave the way for the construction of successful dendrimer-α emitter conjugates for use in 
radiotherapy. 
 
2.1.3. DENDRIMER-AUGER ELECTRON EMITTER CONJUGATES  
Auger electron emitters under investigation in therapy include bromine-77 (77Br), indium-111 
(111In), iodine-123 (123I), and iodine-125 (125I).89 As for α particles, the precise subcellular 
localization of Auger emitters can dramatically affect their killing efficacy, with nuclear 
internalization resulting in significant efficiency compared to localization at the cell surface.90 For 
instance, Auger electrons from neutron-activated Gd(III) are strongly cytotoxic, but only when 
Gd(III) ions have been internalized into cells. The group of Kobayashi91 used G6 PAMAM 
dendrimers conjugated with a DTPA derivative and avidin (Av-G6Gd), for targeted delivery of 
large quantities of Gd(III) into peritoneal carcinomatosis tumor cells with the aim of generating 
Auger emission with an external neutron beam. Av-G6Gd significantly accumulated and 
internalized into tumor cells both in vitro and in vivo, and the cytotoxic effect of the external 




Figure 5. Biodistribution of 153Gd-labeled Av-G6Gd (a), G6Gd (b), and Gd-DTPA (c) at 6 h (black 
bars) and 1 day (hatched bars) after i.p. injection in nude mice bearing SHIN3 intraperitoneal 
disseminated tumors. The data are expressed as the mean percentages of injected dose per gram of 
normal tissues and standard deviation (n = 4-6). All data show significant differences (p < 0.01) 
compared with the appropriate group of data with Gd-DTPA. Reprinted with permission from 
ref.91 Copyright 2001 American Chemical Society. 
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In another example by the same group, an Av-G4 PAMAM-1B4M chelate complex radiolabeled 
with 111In, which emits Auger and conversion electrons, was synthesized for internal radiation 
therapy in intraperitoneal (i.p.) disseminated tumors.92 The chelating sites on Av-G4-(1B4M)52 
were saturated with either radioactive or non-radioactive In(III). The results of this work clearly 
show the capability of Av-Bt-G4-(1B4M)52 to specifically internalize cancer cells. The 
biodistribution studies of both 111In saturated and unsaturated dendrimers in nude mice 
demonstrated high dendrimer concentration in i.p. disseminated tumors with high 
tumor:background ratios. 
In a more recent study,76 G1 and G4 PAMAM dendrimers were conjugated with a bifunctional 
pyridine-N-oxide DOTA analog and radiolabeled with 111In. The conjugate displayed a good 
kinetic stability for at least 48 h after preparation. Biodistribution and elimination in rats was more 
favorable for the G1-111In conjugate than for G4. Thus, while G1-111In conjugate was rapidly 
eliminated from the body, mainly through urine, significant and long-term radioactivity uptake in 
the liver and kidney was observed for G4-111In. 
 
2.1.4. DENDRIMERS IN BORON NEUTRON CAPTURE THERAPY 
Boron neutron capture therapy (BNCT) is a radiation therapy modality accomplished in two 
stages. First, a patient is injected with a non-radioactive pharmaceutical containing a stable isotope 
of boron (10B), which selectively migrates to cancer cells. Next, upon irradiation with a neutral 
beam of low-energy or thermal neutrons boron atoms generate α particles that destroy the tumor, 
leaving normal cells unaffected. In order to sustain a lethal effect a large number of 10B atoms 
must be delivered to each cancer cell.93,94 
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The high cargo loading of dendrimers has been exploited to this end. Various dendrimers 
covalently attached to boron have been prepared and tested with preliminary positive results. A 
methodology was developed to heavily boronate a moAb by coupling to a boronated PAMAM 
dendrimer by means of heterobifunctional reagents.95 These conjugates retained the high in vitro 
immunoreactivity of the moAb, but after intravenous injection they accumulated in the liver. This 
way of injection resulted in a decrease of the in vivo tumor targeting properties of the conjugates. 
In order to avoid this biodistribution hurdle, an intratumoral injection of the boronated dendrimers 
was investigated with encouraging results. Later on, the same group96 has conjugated a heavily 
boronated G5 PAMAM dendrimer (G5-B1100) to the Cetuximab® moAb, as a boron delivery agent 
for BNCT to brain tumor. When injected intracerebrally, the complex showed specific molecular 
targeting of the epidermal growth factor receptor (EGFR), which is often amplified in human 
gliomas. 
In an effort to improve the biodistribution and decrease reticulo-endothelial system (RES) 
uptake, various studies have focused on the modification of boronated PAMAM dendrimers with 
PEG. Since the expression of the folate receptor is amplified in a variety of human tumors, FA is 
frequently used to enhance the tumoral uptake of dendrimers and other nanosystems. In this 
context, the group of Tjarks and coworkers97 evaluated a series of boronated G3 PAMAM 
dendrimers containing 12-15 decaborate clusters, along with PEG chains to minimize hepatic 
uptake and FA for folate receptor targeting. One of the conjugates having an average of one 
PEG2000 chain and one FA-PEG800 resulted in selective tumor uptake (6.0% ID/g tumor) in 
C57BL/6 mice bearing folate receptor (+) murine 24JK-FBP sarcomas. In spite of this result, high 
hepatic (38.8% ID/g) and renal (62.8% ID/g) uptakes were also revealed. The authors concluded 
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that even though the strategy was successful in increasing tumor selectivity, further improvements 
were necessary to optimize biodistribution.  
An alternative strategy to optimize the delivery of boronated dendrimers to tumor cells is the 
incorporation of carborane cages within the dendritic structure (Fig. 6). The group of Adronov98 
synthesized a family of biocompatible water soluble, aliphatic polyester dendrimers that 
incorporate as many as 16 p-carboranes in their interior, as possible candidates for use in BNCT. 
In another example, phenylene-cored carborane dendrimers have been synthesized for BNCT.99 In 
vitro studies with these dendrimers in human liver cancer cells showed a concentration-dependent 
accumulation of the dendrimer conjugates. Similarly, biocompatible Au nanoparticles containing 
carborane clusters and PEG chains attached to dendrons were engineered to provide a BNCT 
platform with potential simultaneous use in photo-thermotherapy, imaging and drug 
vectorization.100  
 
Figure 6. Schematic representation of the incorporation of carboranes into polyester dendrimers. 
Reprinted with permission from ref 98. Copyright 2005 American Chemical Society. 
The photoluminescence of different generations of porphyrin-cored aryl ether dendrimers 
functionalized with carborane clusters has been investigated.101 It was concluded that the 
photoluminescence properties of these dendrimers were not largely affected by the carboranes, 
opening the door for further investigations of these systems for theranostic use in nanomedicine. 
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More recently,102 a dendritic wedge with high boron content for BNCT or boron MRI was 
combined with a monomethine cyanine dye for visible-light fluorescent imaging, and an integrin 
ligand for efficient tumor targeting. This conjugate resulted in a rapid intratumoral accumulation 
and prolonged retention when analyzed in fully established animal models of human melanoma 
and murine mammary adenocarcinoma (Fig. 7).  
 
 
Figure 7. Representative fluorescence images of the in vivo tumor uptake of a trifunctional 
dendritic theranostic agent. Adapted with permission from ref 102. Copyright 2014 American 
Chemical Society. 
2.2. DENDRIMER-ANTIBODY CONJUGATES IN RADIOIMMUNOTHERAPY  
Antibodies have the unique property to bind their targets in a highly selective manner, which 
makes them attractive for the delivery of radiotherapeutics. Phase I clinical trials have been 
performed with monoclonal antibodies (moAbs) radiolabeled with α emitters 213Bi and 211At. 
These systems were evaluated in patients with leukemia and brain tumors,5 respectively, with 
encouraging responses and acceptable levels of toxicity in normal tissues. 
The first bifunctional chelate used to bind 213Bi to moAbs was trans-cyclohexyl diethylene 
triamine pentaacetic acid (CHX-A-DTPA), with a procedure requiring 0.5 h.103 Other ligands 
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derived from DTPA were later on synthesized for the same purpose, including the cyclic anhydride 
of diethylene triamine penta-acetic acid (cDTPAa)104 and p-isothiocyanatobenzyl-DTPA (CITC-
DTPA)105. Zalutsky and coworkers106,107 developed a two-step method for the radiolabeling of 
intact or fragments of chimeric moAbs with 211At using two similar bifunctional chelating agents 
[N-succinimidyl 3-(tri-n-butylstannyl) benzoate (m-BuATE) and N-succinimidyl 3-(tri-n-
methylstannyl) benzoate (m-MeATE)] in a procedure lasting 1.5 h. 
Tumor targeting studies with these radiolabeled moAbs showed, however, some limitations, 
such as insufficient targeting, low accumulation in tumor sites, and undesired irradiation of normal 
tissues associated to low clearance rates of IgG-based radioimmunoconjugates (days to weeks).108 
Also, the introduction of more than one radionuclide per moAbs, to enhance the radioactive dose, 
caused a drastic decrease in immunoreactivity. The attachment of any therapeutic moiety to 
antibodies influences their clearance kinetics, biodistribution and side effects of radio-
immunoconjugates.109 Another important issue in the use of moAbs for targeted radiotherapy was 
the slow reaction kinetics in the formation of the ligand-metal complex, when macrocyclic 
bifunctional chelating ligands, such as DOTA or DTPA derivatives, were attached to them.110,111 
When the number of chelating groups into the structure of moAbs was increased to speed up 
complexation, a substantial loss in immunoreactivity was observed.112 The extent of antibody 
loading is a critical issue for the design of highly effective immunoconjugates, and still largely a 
subject of empirical evaluation. Indeed, amino acids amenable to modification are found along all 
regions of antibodies. Since most modification methods are not site-specific, there is no control 
over which amino acids are modified. This frequently results in immunoconjugates modified at 
positions weakening the binding to the antigen, which in turn decreases the efficacy of the targeting 
system.108 So, one of the actual challenges of immunoconjugation is product homogeneity with 
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regard to site-specificity and stoichiometry of antibody modification.113,114 Site-specifically 
conjugated tumor-targeting antibodies have been shown to exhibit a greater uptake at the cancerous 
site and less non-specific uptake compared to heterogeneous immunoconjugates.115 The most 
challenging issue for radioimmunotherapy (RIT) is to find the correct balance between the dose 
delivered to the tumor and exposure of normal organs and tissues to radiation.116 
Also, in order to improve tumor/blood ratios, antibody fragments lacking the Fc part have been 
tested for radio-immunoconjugation.117 Invariably, however, only a small fraction of the 
administered dose localizes in the tumor, rendering doses delivered to the tumor low for 
therapeutic applications. 
In recent years, to solve these problems, dendritic systems have been conjugated to antibodies 
to preserve their immunoreactivity, while providing high specific activities and efficient 
radiolabeling.88,96,118 Indeed, the branched structure of dendrimers creates a multivalent surface 
with a  high number of peripheral groups, which makes them unique candidates for conjugating to 
antibodies to afford log-fold higher radioactivities than current antibodies with promising 
results.119  
The use of dendrimers for potentially improving delivery of radioimmunotherapy conjugates is 
in its early phases of development. One of the first reports in this area came from Roberts and 
coworkers,120 who conjugated PAMAM dendrimers to IgG-antibodies in a two-step process and 
demonstrated for the first time that their immunoreactivity remained largely unaffected after 
dendrimer conjugation using sensitive enzyme linked immunoassays (ELISA).  
In 1999 the group of Kobayashi121 described the biodistribution of 111In and 88Y labelled G2 
PAMAM dendrimers conjugated to 1B4M and an anti-Tac IgG antibody. Tumor xenografts were 
generated in 5-6-week-old female athymic nude mice, with ATAC4 cell line. High tumor 
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absorption of the conjugates was observed, although accompanied by high accumulation in liver, 
kidney and spleen that could be decreased by saturating the chelates with cold metals. 
Interestingly, saturation of the 1B4M chelates with Y(III) was shown to be more effective to 
decrease liver and spleen accumulation, in comparison with In(III). This fact probably relates a 
lower stability of the In(III) chelates in vivo that results in free 1B4M ligands and concomitant 
faster opsonization and uptake by RES. 
In a more recent study by the same group,122 G4 PAMAM dendrimers conjugated to 1B4M and 
OST7, a murine monoclonal IgG1, were labeled with 111In and 153Gd. The radiometal labeling was 
achieved with very high specific radioactivity and minimal loss of immunoreactivity. 
Biodistribution studies in a mice model with KT005-specific tumors, showed specific tumor 
accumulation and rapid blood clearance. Again, the saturation of the 1B4M ligands with Gd(III) 
was more effective in decreasing liver and spleen accumulation than with In(III). Additionally, 
clearance times of unsaturated preparations were significantly slower than those of the saturated 
ones. As a result, it can be concluded that charge and molecular weight are not the only factors 
affecting biodistribution, and that the surface functionalization of dendrimers is critical to reduce 
their liver and spleen uptake.  
The tumor selectivity of dendrimer-antibody conjugates has been investigated by Baker and 
coworkers.118 PAMAM dendrimers were conjugated to two different antibodies, 60bca and J591, 
which bind to CD14 and prostate-specific membrane antigen (PSMA), respectively. It was 
revealed that the antibody-conjugated dendrimers specifically bind to the antigen-expressing cells 
in a time and dose-dependent manner, with affinity similar to that of the free antibodies. 
To study the effect of dendrimer size and number on the immunoreactivity of moAbs, several 
DOTA-containing PAMAM dendrimers of different generations were synthesized and conjugated 
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to antibodies for radioimmunotherapy and clinical diagnostics (Fig. 8).123 It was concluded that 
the dendrimer size does not significantly influence the immunoreactivity of the conjugated 
antibody over a wide range of molecular weights, whereas increasing the number of conjugation 
sites has a clear detrimental effect. Therefore, to obtain conjugates that result in a minor 
compromise of immunoreactivity, antibodies should be functionalized with few large dendritic 
systems. Further studies are necessary to establish the clinical usefulness of dendrimer-conjugates 
for radioimmunotherapy 
 
Figure 8. Scheme of the conjugation of DOTA-dendrimers to an antibody. Adapted with 
permission from ref 123. Copyright 2008 American Chemical Society. 
2.3. DENDRIMERS IN GENE DELIVERY RADIOTHERAPY 
2.3.1. DENDRIMERS IN RADIOVIROTHERAPY 
Radiovirotherapy is an innovative strategy for radioisotopic therapy that uses oncolytic viruses 
able to selectively target and kill cancer cells.124 The combination of oncolytic viruses and 
radiation can have synergistic antitumor properties by selectively delivering radiation therapy to 
tumor cells.  
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The sodium/iodide symporter (NIS) is the main transgene that has been studied with this aim.125 
NIS, is a trans-membrane glycoprotein that has a crucial role in the biosynthesis of thyroid 
hormones126 that is also known to be able to mediate the uptake of radionuclides, such as 131I, 188Re 
or 211At. While NIS expression in thyroid cancers decreases as the cancer cell differentiation 
decreases,127 NIS expression is found in a number of other non-thyroid cancers, like breast and 
liver.128-130 While, NIS expression in breast cancer cells is stimulated by retinoic acid (RA), 
estrogen and glucocorticoids, in the stomach the expression is generally suppressed during 
carcinogenesis. In liver cancers, NIS is expressed in all cholangiocarcinomas (CCA) and in a small 
proportion of hepatocellular carcinomas (HCC). 
Accordingly, the use of a viral vector for NIS gene transfer to infected tumor cells is envisaged 
as a mean to improve the delivery of radioisotopes. Among the oncolytic viruses for this purpose, 
adenoviruses are the preferred vectors as they are known to selectively infect and replicate in 
cancer cells. Adenovirus-mediated gene therapy has nevertheless some limitations, such as high 
prevalence of neutralizing antibodies, widespread expression of the coxsackie-adenovirus receptor 
(CAR) and unexpected interactions with host proteins in vivo. In addition, targeting adenoviruses 
to receptors on hepatocytes results in vector sequestration in liver.131 Therefore with the aim of 
improving an efficacious targeting to tumor sites and limit nonspecific uptake of viruses to non-
target tissues (mainly liver and spleen) it has been necessary to develop suitable strategies to 
modify the capsid proteins on the virus shell, including the use of dendrimer coatings.  
With the aim of developing adenoviral vectors for a combined systemic oncolytic virotherapy 
and NIS-mediated radiotherapy, the groups of Spitzweg and Ogris132 in collaboration recently used 
PAMAM dendrimers with positively charged terminal amines to coat the negatively charged 
adenoviral capsid of Ad5-E1/AFP-E3/NIS by electrostatic interactions. NIS expression was 
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followed with noninvasive imaging by 123I scintigraphy. In vivo tests in a liver cancer xenograft 
mouse model (Fig. 9) showed significantly lower hepatic accumulation of 123I after systemic 
application. More importantly, the combined radiovirotherapy using the dendrimer-coated Ad5-
E1/AFP-E3/NIS (dc300Ad5-E1/AFP-E3/NIS), followed by a single application of a therapeutic 
dose of 131I, resulted in a stronger stimulation of the therapeutic effect, as observed by an 
extensively delayed tumor growth and prolonged survival in comparison with virotherapy alone 
or with control groups using the uncoated vector.  
 
Figure 9. 123I scintigraphy confirms significantly increased levels of tumor-specific iodide 
accumulation after application of coated adenovirus (A) as compared with injection of uncoated 
virus (B). Reprinted from ref 132, copyright by the Society of Nuclear Medicine and Molecular 
Imaging, Inc. 
In another study from the same group,133 tumor-selective iodide uptake and therapeutic efficacy 
of combined radiovirotherapy was reported after systemic delivery of a theranostic NIS gene using 
a dendrimer-coated adenovirus. In this case the dendritic coating consisted of PAMAM dendrimers 
linked to an EGFR specific peptide ligand (GE11). As above, injection of the uncoated adenovirus 
in a liver cancer xenograft mouse model led to high levels of NIS expression in the liver due to 
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hepatic sequestration, which were significantly reduced after dendrimer coating as demonstrated 
by 123I-scintigraphy. The EGFR targeting specificity was confirmed by 124I-PET-imaging (Fig.10), 
showing a significantly lower tumoral radioiodine accumulation after pretreatment with the EGFR-
specific antibody cetuximab. The enhanced oncolytic effect following systemic application of the 
dendrimer-coated adenovirus was further increased by additional treatment with a therapeutic dose 
of 131I (Fig.10). 
Altogether, these results show that coating of adenoviral vectors with synthetic dendrimers is a 
promising strategy for effective adenovirus liver detargeting and tumor retargeting, taking 
advantage of the merging of nonviral and viral vector technologies. 
  
 
Figure 10. 124I-PET-imaging shows that the strong hepatic transduction after i.v. injection of an 
uncoated adenoviral vector (Ad5-E1/AFP-RSV/NIS) (a) is significantly reduced by coating with 
PAMAM-G2 linked to peptide GE11 (dc300/GE11Ad5-E1/AFP-RSV/NIS) (b), even when mice are 
treated with the monoclonal anti-EGFR antibody cetuximab before systemic administration (c). 
Significantly higher transduction of tumor xenografts was observed in (b) than (c). Adapted with 




2.3.2. DENDRIMERS IN COMBINED NON-VIRAL GENE DELIVERY AND 
RADIOTHERAPY 
Since dendrimers by their own provide efficient and safe non-viral vectors for the delivery of 
genes into target cells,134 they have been also assayed for gene delivery radiotherapy. In a pre-
clinical study, the groups of Spitzweg and Ogris135 used G2 oligoethylenimine (OEI)-grafted 
polypropylenimine dendrimers (PPI) as novel and highly efficient nonviral gene delivery vehicles 
for systemic NIS gene transfer (G2-HD-OEI/NIS) in a syngeneic neuroblastoma mouse model. 
Based on its dual function as reporter and gene therapy, NIS was used for noninvasive imaging of 
the biodistribution of the dendrimer conjugates by 123I-scintigraphy, followed by assessment of the 
therapy response after application of 131I. Tumor-specific iodide accumulation was shown to be 
sufficiently high for a significant delay of tumor growth, as observed by an increased survival rate 
after application of two cycles of NIS-dendrimer conjugates followed by 131I radiotherapy.  
In a more recent contribution,136 the radiosensitivity of human uveal primary tumor, which is the 
most common primary intraocular tumor, was efficiently improved in vitro, when dendrimers were 
used as a vector to produce coexpression gene therapy of TNFα and HSV-TK, followed by 
exposure to 125I after transfection. 
3. CONCLUSIONS AND FUTURE PERSPECTIVES 
In order to improve the efficacy of internal radiotherapy as one of the most commonly used 
cancer treatments, nuclear medicine has recently turned the attention to new oncologic strategies 
based on nanovectorization, often referred to as radionanomedicine. The ultimate aim is to 
efficiently target and retain radiation at the tumor site, avoiding side effects, such as toxicity and 
tumor resistance process. Thus, it is known that nanosystems with long circulation times in the 
blood stream can get internalized and retained into tumors thanks to a leaky vasculature and an 
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abnormal lymphatic drainage. This effect, known as EPR, can be further assisted by the use of 
targeting agents. The objective of radionanotherapy is the labeling of nanosystems with 
radionuclides to improve the efficiency of the treatment, while reducing the dose of radiolabeled 
materials in vivo. Among the nanosystems described for this purpose, dendrimers are especially 
appealing because of their multivalency, tunable size and physicochemical properties as a function 
of the generation. Milestones in the development of dendrimers for nanovectorized radiotherapy 
include their functionalization with ligands for radiolabeling, targeting agents, and stealth 
functional groups to potentially improve their biodistribution, circulation times and stability in 
vivo.  
The active role of dendrimers as innovative radiopharmaceuticals is reviewed with a special 
focus on critical challenges encountered in the advance of targeted radiotherapy. As discussed, the 
radiolabeling of dendrimers with therapeutic radionuclides has resulted in tumor regression and 
longer survival. The biodistribution of dendritic conjugates can be improved by PEGylation, 
intratumoral application, saturation with cold metals, or by modulating their charge and molecular 
weight. In addition, the multifunctionality of dendrimers makes them excellent candidates for 
theranostics. For instance, optimized delivery of boron compounds to tumor cells was achieved by 
incorporating carborane cages within biodegradable dendrimers, which proved useful as 
theranostic agents in a combined use of BNCT, photo-thermotherapy, imaging and drug 
vectorization. The development of radiotherapeutic dendrimers for image-guided radionuclide 
therapies is also a work in progress. The multivalency and precise architecture of dendrimers can 
be exploited for radiotherapy in combination with moAbs, a strategy that pursues minor changes 
in immunoreactivity. Finally, dendrimers have been investigated in radiovirotherapy as coatings 
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of adenoviral vectors for effective liver detargeting and tumor retargeting, as well as non-viral 
gene delivery vectors for NIS-targeted radionuclide therapy of metastatic cancer. 
Although issues associated with in vivo properties and the toxicity of dendrimer conjugates are 
challenges to be addressed individually, as a whole there are considerable promise and benefits on 
current applications of dendrimers for radionanotherapy. A proper evaluation of dendrimer-based 
radiopharmaceuticals must be appreciated according to three criteria: the choice of radionuclide, 
the vector used, and the modalities of administration. Relatively recent results on dendrimer-based 
radiopharmaceuticals in preclinical models do not permit such a comparison yet. As discussed in 
this review, the physico-chemical properties of the radionuclide are crucial, but differences 
between vectors (untargeted vs targeted dendrimer, different dendrimer generations) are 
appreciated after intravenous injections with the aim of qualifying the targeting rather than the 
efficacy. In fact, for medical applications with radiopharmaceuticals, loco-regional injection could 
be a preferred way, where dendrimers play the role of confining agent at the injection site, in order 
to reduce the associated radio toxicity on healthy tissues or organs. Targeting will increase this 
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